VACC News and Press, Vaccitech plc From 09/20/22

Vaccitech ( NASDAQ: VACC ) said Tuesday it promoted Gemma Brown to the CFO role, succeeding Georgy Egorov. Brown joined VACC as head of financial reporting in 2021, before her promotion to CFO. For further details see: Vaccitech promotes Gemma Brown to CFO ...

OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer (CFO...

Summary Today, we revisit Arbutus Biopharma Corporation for the first time in almost a year. An interesting 'sum of the parts' story seems to be emerging around the company and the stock. An investment analysis follows in the paragraphs below. "I could easily for...

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enri...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers for Thursday! Moving stocks this morning are earnings reports, an analyst upgrade, and m...

Vaccitech press release ( NASDAQ: VACC ): Q2 GAAP EPS of $0.41. License Revenue of $17.06M. As of June 30, 2022, cash and cash equivalents were $192.3 million, compared to $214.1 million as of December 31, 2021. For further details see: Vaccitech GAAP EPS of ...

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceut...

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enrig...

Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a triple combination regimen with AB-729; In addition, potential to advance very same drug f...

Vaccitech (NASDAQ:VACC) plans to offer 2.16M shares represented by ADS offered by selling stockholders. The ADSs being offered were issued to the selling shareholders as part of the company acquisition of Avidea Technologies in December 2021. The company will receive no proceeds from sale of ...